Biopharmaceutical leader in the development of treatments for rare diseases
H.R. 1314: Trade Preferences Extension Act as it relates to access to orphan drug therapies. H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO). Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.

H.R. 6: 21st Century Cures Act.

Education about the value of innovative new medicines. Educated staff about access to therapies for rare diseases.

Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
TRD - Trade (domestic/foreign) CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX DARREN WILLCOX DARREN WILLCOX